• Thurs news: Amgen reaps Horizon buyout rewards in Q3. Baxter exits China IV market. Big Pharma earnings. Novo takes steps to end shortages. Roche Alzheimer’s test. See more on our front page


Kenvue CEO replacement













If Kenvue follows the JNJ model, he should be just fine. JNJ has a long history of hanging on to medicore senior leaders for long, long periods of time.

Kenvue leaders (who are J&J veterans) may want to follow the J&J model, but no longer can they hide in the deep Pharma pockets. Investors are looking for returns and the grace period is running out. Thibaut has maybe two more quarters to show progress before the Wall Street will turn on Kenvue. The old guard from J&J cannot bootstrap this, so the sooner we hit rock bottom and reboot the leadership layer, the better.